{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:17:05Z","timestamp":1788844625496,"version":"build-2803163510"},"reference-count":0,"publisher":"American Medical Association (AMA)","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2024,5,14]]},"abstract":"<jats:p>This Medical News story examines other potential uses of GLP-1 receptor agonists, the popular type 2 diabetes and weight-loss drugs.<\/jats:p>","DOI":"10.1001\/jama.2024.1017","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T11:36:33Z","timestamp":1713526593000},"page":"1519","source":"Crossref","is-referenced-by-count":34,"title":["Could GLP-1 Receptor Agonists Like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions?"],"prefix":"10.1001","volume":"331","author":[{"given":"Rita","family":"Rubin","sequence":"first","affiliation":[{"name":"Lead Senior Staff Writer, Medical News & Perspectives, JAMA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2817996\/jama_rubin_2024_mn_240007_1714681241.6263.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T11:01:27Z","timestamp":1715684487000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2817996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":0,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024,5,14]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2024.1017","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,14]]}}}